60 Degrees Pharmaceuticals, Inc. (SXTP)
NASDAQ:SXTP
SXTP Stock Chart & Stats
$0.50
-$0.08(-5.71%)
At close: 4:00 PM EST
$0.50
-$0.08(-5.71%)
Day’s Range― - ―
52-Week Range$1.29 - $17.68
Previous CloseN/A
Volume13.44M
Average Volume (3M)199.18K
Market Cap
$3.71M
Enterprise Value-$2.75M
Total Cash (Recent Filing)$4.12M
Total Debt (Recent Filing)$153.76K
Price to Earnings (P/E)―
Beta2.40
Next Earnings
May 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,472,949
10 Day Avg. Volume488,900
30 Day Avg. Volume199,179
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.73
Price to Sales (P/S)4.83
P/FCF Ratio-0.50
Enterprise Value/Market Cap-0.74
Enterprise Value/Revenue-2.86
Enterprise Value/Gross Profit-14.92
Enterprise Value/Ebitda0.35
Forecast
1Y Price Target
$24.00Price Target Upside4700.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-6.9
Revenue Forecast (FY)$2.05M
Bulls Say, Bears Say
Bulls Say
Distribution PartnershipAnalyst notes the GoodRx partnership lowers patient out-of-pocket costs and expands nationwide availability for ARAKODA, which could accelerate sales growth as more patients gain access.
Market Expansion And Indication GrowthAnalyst points out company initiatives on awareness, physician outreach, payer and pharmacy engagement, and exploration of additional indications like babesiosis could broaden ARAKODA's addressable market and support longer-term uptake in a large infectious disease market.
Telehealth Access For TravelersAnalyst highlights the Runway Health telehealth tie-up expands pre-departure access by matching travel itineraries with personalized treatment plans, creating a new channel to reach international travelers.
Bears Say
Commercial Execution RiskAnalyst warns that dependence on awareness campaigns and payer and pharmacy negotiations to lower out-of-pocket costs creates execution risk if these efforts fail to materially improve patient access.
Conversion To Sustainable RevenueAnalyst notes increased visibility may not convert quickly to sustained revenue, which could extend the period of limited sales and pressure the stock.
Sales TractionAnalyst cautions that ARAKODA sales remain modest, signaling the need for stronger commercial traction to translate partnerships into meaningful revenue.
60 Degrees Pharmaceuticals, Inc. News
SXTP FAQ
What was 60 Degrees Pharmaceuticals, Inc.’s price range in the past 12 months?
60 Degrees Pharmaceuticals, Inc. lowest stock price was $1.29 and its highest was $17.68 in the past 12 months.
What is 60 Degrees Pharmaceuticals, Inc.’s market cap?
60 Degrees Pharmaceuticals, Inc.’s market cap is $3.71M.
When is 60 Degrees Pharmaceuticals, Inc.’s upcoming earnings report date?
60 Degrees Pharmaceuticals, Inc.’s upcoming earnings report date is May 14, 2026 which is in 47 days.
How were 60 Degrees Pharmaceuticals, Inc.’s earnings last quarter?
Currently, no data Available
Is 60 Degrees Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts 60 Degrees Pharmaceuticals, Inc.’s price is currently Undervalued.
Does 60 Degrees Pharmaceuticals, Inc. pay dividends?
60 Degrees Pharmaceuticals, Inc. does not currently pay dividends.
What is 60 Degrees Pharmaceuticals, Inc.’s EPS estimate?
60 Degrees Pharmaceuticals, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 60 Degrees Pharmaceuticals, Inc. have?
60 Degrees Pharmaceuticals, Inc. has 2,472,949 shares outstanding.
What happened to 60 Degrees Pharmaceuticals, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of 60 Degrees Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in SXTP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. The company was founded in 2010 and is headquartered in Washington, District Of Columbia.
SXTP Stock 12 Month Forecast
Average Price Target
$24.00
▲(4700.00% Upside)
Technical Analysis
Ownership Overview
Options Prices
Currently, No data available
---